Skip to main content
HLB INC. logo

HLB INC. — Investor Relations & Filings

Ticker · 028300 ISIN · KR7028300002 KO Manufacturing
Open in API
Filings indexed 553 across all filing types
Latest filing 2022-10-12 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 028300

About HLB INC.

https://www.hlb.global/

HLB INC. is a biopharmaceutical company focused on developing new global anti-cancer drugs. The company's core activities center on advancing a pipeline of novel therapeutics through its worldwide network, which includes subsidiaries like Elevar Therapeutics and Immunomic Therapeutics. In addition to its primary focus on oncology, HLB's affiliated companies are involved in other life science areas, such as developing and manufacturing in vitro diagnostic medical devices, peptide-based biomaterials, and quasi-drugs. The group also has operations in composite materials and shipbuilding, reflecting its diversified origins.

Recent filings

Filing Released Lang Actions
[발행조건확정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the issuance price (1차발행가액 확정) for a capital increase (유상증자). This type of filing is a regulatory document related to capital structure changes and financing activities. According to the provided definitions, 'CAP' (Capital/Financing Update) is the most appropriate category for documents detailing fundraising and financing activities, including securities registration statements.
2022-10-12 Korean
투자설명서
Investor Presentation Classification · 1% confidence The document is a '투자설명서' (Investment Prospectus) issued by HLB Co., Ltd. on October 12, 2022. It details a capital increase (rights offering/public offering), including offering price, subscription periods, and extensive risk factors related to the company's business, financials, and clinical trials. In the context of financial filings, a prospectus for a securities offering is classified as a Proxy Solicitation & Information Statement (PSI) or a regulatory filing related to capital raising. Given the specific categories provided, 'PSI' is the most appropriate fit for a formal investment prospectus document.
2022-10-12 Korean
유상증자1차발행가액결정
Share Issue/Capital Change Classification · 1% confidence The document is an official announcement regarding the determination of the first issue price for a capital increase (paid-in capital increase/rights offering) by HLB. It details the number of shares, the calculated price, and the methodology used for the pricing. This falls under the category of share issuance and capital changes.
2022-10-12 Korean
권리락(유상증자)
Share Issue/Capital Change Classification · 1% confidence The document is a short notice regarding '권리락' (ex-rights) due to a capital increase (유상증자) for HLB. It provides specific details such as the reference price and the effective date. This falls under the category of announcements regarding capital changes or share issues.
2022-10-12 Korean
[기재정정]증권신고서(지분증권) (2022.11)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by HLB Co., Ltd. in South Korea. It details specific amendments to previously filed registration statements, including updates to business risks, clinical trial statuses, and financial information. In the context of financial document classification, a Securities Registration Statement (and its amendments) is a regulatory filing that provides detailed information about a company's business, risks, and financial status to regulators and investors. Since it does not fit into specific categories like 10-K (Annual Report) or ER (Earnings Release), and is a formal regulatory submission, it is classified as a Regulatory Filing (RNS).
2022-10-11 Korean
[기재정정]증권신고서(지분증권) (2022.11)
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by HLB Co., Ltd. It details amendments (정정신고) to previously filed information, specifically regarding investment risk factors, business operations, and legal opinions on credit extensions. This type of document is a formal regulatory filing required by the Financial Supervisory Service (FSS) in South Korea for companies issuing securities or updating their registration statements. It does not fit into specific categories like 'Annual Report' (10-K) or 'Earnings Release' (ER), but rather serves as a formal regulatory disclosure.
2022-10-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.